X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (51625) 51625
Newsletter (969) 969
Book Chapter (117) 117
Newspaper Article (82) 82
Magazine Article (53) 53
Dissertation (15) 15
Publication (14) 14
Conference Proceeding (9) 9
Book / eBook (8) 8
Book Review (4) 4
Reference (3) 3
Government Document (2) 2
Journal / eJournal (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (42217) 42217
female (24831) 24831
male (23085) 23085
oncology (21551) 21551
adenocarcinoma - drug therapy (20209) 20209
middle aged (20113) 20113
adenocarcinoma (18763) 18763
aged (18129) 18129
cancer (16347) 16347
adult (12809) 12809
adenocarcinoma - pathology (12001) 12001
chemotherapy (11068) 11068
animals (9196) 9196
antineoplastic combined chemotherapy protocols - therapeutic use (8288) 8288
prognosis (7500) 7500
treatment outcome (6613) 6613
carcinoma (6351) 6351
mice (6311) 6311
lung neoplasms - drug therapy (6253) 6253
cell line, tumor (6146) 6146
aged, 80 and over (6120) 6120
tumors (6096) 6096
metastasis (5905) 5905
research (5720) 5720
surgery (5621) 5621
care and treatment (5608) 5608
neoplasm staging (5527) 5527
pancreatic cancer (5267) 5267
expression (5263) 5263
survival (5144) 5144
lung cancer (4984) 4984
apoptosis (4859) 4859
adenocarcinoma - surgery (4808) 4808
antineoplastic agents - therapeutic use (4776) 4776
lung neoplasms - pathology (4646) 4646
adenocarcinoma - metabolism (4540) 4540
adenocarcinoma - genetics (4454) 4454
analysis (4356) 4356
adenocarcinoma - secondary (4323) 4323
therapy (4178) 4178
combined modality therapy (3990) 3990
survival rate (3978) 3978
retrospective studies (3847) 3847
adenocarcinoma - mortality (3805) 3805
health aspects (3790) 3790
mutation (3733) 3733
medicine & public health (3563) 3563
fluorouracil - administration & dosage (3552) 3552
pancreatic neoplasms - drug therapy (3516) 3516
cancer therapies (3449) 3449
follow-up studies (3282) 3282
lung neoplasms - genetics (3240) 3240
adenocarcinoma - therapy (3231) 3231
stomach neoplasms - drug therapy (3231) 3231
gene expression (3173) 3173
genetic aspects (3145) 3145
immunohistochemistry (3105) 3105
gastroenterology & hepatology (3060) 3060
pancreatic neoplasms - pathology (2937) 2937
survival analysis (2900) 2900
proteins (2880) 2880
cisplatin - administration & dosage (2875) 2875
patients (2821) 2821
gemcitabine (2809) 2809
cisplatin (2801) 2801
adenocarcinoma - radiotherapy (2779) 2779
antineoplastic agents - pharmacology (2777) 2777
disease-free survival (2742) 2742
stomach neoplasms - pathology (2713) 2713
chemotherapy, adjuvant (2701) 2701
medical prognosis (2691) 2691
deoxycytidine - analogs & derivatives (2682) 2682
drug therapy (2670) 2670
pharmacology & pharmacy (2633) 2633
colorectal cancer (2629) 2629
radiotherapy (2562) 2562
carcinoma, squamous cell - drug therapy (2509) 2509
development and progression (2478) 2478
apoptosis - drug effects (2457) 2457
carcinoma, non-small-cell lung - drug therapy (2442) 2442
pathology (2439) 2439
prostatic neoplasms - drug therapy (2435) 2435
antineoplastic combined chemotherapy protocols - adverse effects (2409) 2409
cell biology (2388) 2388
risk factors (2338) 2338
time factors (2325) 2325
mice, nude (2301) 2301
drug administration schedule (2286) 2286
kinases (2240) 2240
tumor cells, cultured (2233) 2233
metastases (2232) 2232
medicine (2227) 2227
diagnosis (2222) 2222
neoplasm metastasis (2222) 2222
research article (2164) 2164
growth (2149) 2149
trial (2130) 2130
cell proliferation - drug effects (2067) 2067
cells (2061) 2061
gene expression regulation, neoplastic (2035) 2035
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (49694) 49694
Japanese (1976) 1976
French (661) 661
German (542) 542
Chinese (387) 387
Spanish (251) 251
Russian (235) 235
Italian (160) 160
Portuguese (50) 50
Polish (40) 40
Hungarian (30) 30
Danish (21) 21
Korean (16) 16
Czech (14) 14
Dutch (13) 13
Romanian (13) 13
Norwegian (11) 11
Ukrainian (10) 10
Bulgarian (8) 8
Swedish (8) 8
Turkish (7) 7
Croatian (5) 5
Lithuanian (5) 5
Hebrew (3) 3
Finnish (2) 2
Serbian (2) 2
Slovak (2) 2
Afrikaans (1) 1
Persian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature (London), ISSN 1476-4687, 2015, Volume 520, Issue 7547, pp. 368 - 372
Drug resistance invariably limits the clinical efficacy of targeted therapy with kinase inhibitors against cancer(1,2... 
CNS CELL-TYPES | MELANOMA | METASTASIS | MICROENVIRONMENT | TRANSLATIONAL PROFILING APPROACH | MULTIDISCIPLINARY SCIENCES | RAF INHIBITOR RESISTANCE | ACQUIRED-RESISTANCE | KINASE INHIBITORS | DRUG-RESISTANCE | CANCER CHEMORESISTANCE | Lung Neoplasms - drug therapy | Adenocarcinoma - pathology | Clone Cells - drug effects | Humans | Lung Neoplasms - metabolism | Lung Neoplasms - pathology | Proto-Oncogene Proteins c-fos - deficiency | Adenocarcinoma - metabolism | Anaplastic Lymphoma Kinase | Neoplasm Metastasis - drug therapy | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Female | Proto-Oncogene Proteins c-akt - metabolism | Melanoma - metabolism | Tumor Microenvironment - drug effects | Cell Survival - drug effects | ErbB Receptors - antagonists & inhibitors | Melanoma - pathology | Down-Regulation - drug effects | Enzyme Activation - drug effects | Adenocarcinoma - drug therapy | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Cell Movement - drug effects | Animals | Clone Cells - pathology | Metabolome - drug effects | Signal Transduction - drug effects | Neoplasm Metastasis - pathology | Protein Kinase Inhibitors - therapeutic use | Melanoma - drug therapy | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Drug Resistance, Neoplasm - drug effects | Antimitotic agents | Pharmaceutical research | Care and treatment | Oncology, Experimental | Dosage and administration | Research | Drug therapy | Drug resistance | Antineoplastic agents | Tumors | Cancer | Melanoma | Mutation | Metastasis | Kinases | Cancer therapies
Journal Article
Gynecologic oncology, ISSN 0090-8258, 2014, Volume 135, Issue 2, pp. 223 - 230
Abstract Objectives Complete surgery with no macroscopic residual disease (RD) at primary (PDS) or interval debulking surgery (IDS) is the main objective of... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | Neoadjuvant chemotherapy | Number of cycles | Interval surgery | Prognosis | Epithelial ovarian cancer | Number of cycles Prognosis | SURVIVAL | TRIALS | CYTOREDUCTIVE SURGERY | METAANALYSIS | SENSITIVITY | RESIDUAL DISEASE | OBSTETRICS & GYNECOLOGY | ONCOLOGY | ADVANCED-STAGE OVARIAN | RESISTANCE | PRIMARY DEBULKING SURGERY | CARCINOMA | Adenocarcinoma - pathology | Adenocarcinoma, Mucinous - pathology | Carcinosarcoma - surgery | Humans | Middle Aged | Ovarian Neoplasms - pathology | Cystadenocarcinoma, Serous - pathology | Cystadenocarcinoma, Serous - drug therapy | Cytoreduction Surgical Procedures | Young Adult | Carcinoma, Endometrioid - surgery | Adenocarcinoma, Mucinous - surgery | Aged, 80 and over | Adult | Female | Neoadjuvant Therapy | Retrospective Studies | Adenocarcinoma, Mucinous - drug therapy | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Adenocarcinoma, Clear Cell - surgery | Carcinosarcoma - pathology | Neoplasms, Glandular and Epithelial - pathology | Reoperation | Treatment Outcome | Carcinoma, Endometrioid - drug therapy | Adenocarcinoma - drug therapy | Cystadenocarcinoma, Serous - surgery | Neoplasms, Glandular and Epithelial - surgery | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Adenocarcinoma, Clear Cell - pathology | Aged | Carcinosarcoma - drug therapy | Platinum Compounds - administration & dosage | Carcinoma, Endometrioid - pathology | Adenocarcinoma - surgery | Adenocarcinoma, Clear Cell - drug therapy | Cohort Studies | Ovarian Neoplasms - surgery | Cancer patients | Care and treatment | Surgery | Adjuvant treatment | Ovarian cancer | Cancer | Life Sciences
Journal Article
BMC cancer, ISSN 1471-2407, 2017, Volume 17, Issue 1, pp. 401 - 10
Journal Article
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 7, pp. 976 - 983
Journal Article
Journal Article
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 6, pp. 747 - 756
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2015, Volume 112, Issue 8, pp. 2473 - 2478
The malignant progression of pancreatic ductal adenocarcinoma (PDAC) is accompanied by a profound desmoplasia, which forces proliferating tumor cells to... 
PROTEIN | MULTIDISCIPLINARY SCIENCES | GLYCOLYSIS | pancreatic cancer | PATHWAY | PROSTATE-CANCER | LIPID RAFTS | cholesterol | S-PHASE | metabolism | gemcitabine | CELL-CYCLE | KRAS | ACCUMULATION | SIMVASTATIN | LDLR | Adenocarcinoma - pathology | Epithelial Cells - metabolism | Gene Silencing - drug effects | Pancreatic Neoplasms - metabolism | Prognosis | Epithelial Cells - drug effects | Humans | Deoxycytidine - pharmacology | Extracellular Signal-Regulated MAP Kinases - metabolism | Pancreatic Neoplasms - drug therapy | Deoxycytidine - therapeutic use | Adenocarcinoma - metabolism | Lipoproteins - metabolism | Clone Cells | Gene Expression Regulation, Neoplastic - drug effects | Receptors, LDL - genetics | Pancreatic Neoplasms - pathology | Adenocarcinoma - enzymology | Pancreatic Neoplasms - enzymology | Receptors, LDL - metabolism | Epithelial Cells - pathology | Up-Regulation - genetics | Cholesterol - metabolism | Adenocarcinoma - drug therapy | Up-Regulation - drug effects | Metabolic Networks and Pathways - genetics | Phenotype | Animals | MAP Kinase Signaling System - drug effects | Cell Compartmentation - drug effects | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Metabolic Networks and Pathways - drug effects | Deoxycytidine - analogs & derivatives | Pancreatic cancer | Carcinoma, Ductal | Development and progression | Genetic aspects | Genetic transcription | Cholesterol metabolism | Health aspects | Biological Sciences
Journal Article
Immunity (Cambridge, Mass.), ISSN 1074-7613, 2016, Volume 44, Issue 2, pp. 343 - 354
Journal Article
Journal of controlled release, ISSN 0168-3659, 2010, Volume 141, Issue 2, pp. 137 - 144
.... In this study, we investigated the anticancer efficacy of doxorubicin in combination with photodynamic therapy using methylene blue in a drug-resistant mouse tumor model... 
Nanoparticles | Chemotherapy | Reactive oxygen species | Drug efflux | Drug resistance | Photosensitizer | Adenocarcinoma - pathology | Antibiotics, Antineoplastic - pharmacology | Apoptosis - drug effects | Methylene Blue - metabolism | Dioctyl Sulfosuccinic Acid - chemistry | Microvessels - pathology | Drug Resistance, Neoplasm | Doxorubicin - chemistry | Mammary Neoplasms, Experimental - metabolism | Photochemotherapy | Drug Carriers | Adenocarcinoma - metabolism | Antibiotics, Antineoplastic - chemistry | Biological Transport | Time Factors | Mammary Neoplasms, Experimental - pathology | Drug Compounding | Female | Mammary Neoplasms, Experimental - blood supply | Doxorubicin - metabolism | Glucuronic Acid - chemistry | Doxorubicin - administration & dosage | Mammary Neoplasms, Experimental - drug therapy | Microvessels - drug effects | Hexuronic Acids - chemistry | Methylene Blue - pharmacology | Adenocarcinoma - drug therapy | Chemistry, Pharmaceutical | Adenocarcinoma - blood supply | Antibiotics, Antineoplastic - administration & dosage | Methylene Blue - administration & dosage | Animals | Alginates - chemistry | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C | Antibiotics, Antineoplastic - metabolism | Methylene Blue - chemistry | Doxorubicin - pharmacology | Anthracyclines | Oncology, Experimental | Research | Polysaccharides | Surface active agents | Analysis | Pharmacy | Drug therapy, Combination | Drug therapy | Cancer | Dyes and dyeing
Journal Article
Endocrine-related cancer, ISSN 1479-6821, 2015, Volume 22, Issue 6, pp. 877 - 887
Effective adverse event (AE) management is critical to maintaining patients on anticancer therapies... 
Adverse events | Targeted therapy | Tyrosine kinase inhibitor | Sorafenib | Differentiated thyroid cancer | targeted therapy | sorafenib | EFFICACY | GUIDELINES | TIME | adverse events | differentiated thyroid cancer | DECREASES | TRIAL | ONCOLOGY | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | tyrosine kinase inhibitor | RENAL-CELL | EXPOSURE | Adenoma, Oxyphilic - enzymology | Dyspnea - chemically induced | Thyroid Neoplasms - enzymology | Prevalence | Adenocarcinoma, Follicular - radiotherapy | Humans | Middle Aged | Drug Resistance, Neoplasm | Hypertension - drug therapy | Male | Antineoplastic Agents - therapeutic use | Fatigue - chemically induced | Protein Kinase Inhibitors - adverse effects | Weight Loss - drug effects | Incidence | Neoplasms, Second Primary - chemically induced | Adenocarcinoma, Follicular - drug therapy | Adenoma, Oxyphilic - drug therapy | Hypocalcemia - epidemiology | Niacinamide - adverse effects | Carcinoma, Papillary - drug therapy | Niacinamide - therapeutic use | Thyroid Neoplasms - radiotherapy | Adenocarcinoma, Follicular - enzymology | Neoplasms, Second Primary - epidemiology | Niacinamide - analogs & derivatives | Diarrhea - epidemiology | Diarrhea - chemically induced | Iodine Radioisotopes - therapeutic use | Hypocalcemia - chemically induced | Drug Eruptions - drug therapy | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Hypertension - chemically induced | Female | Carcinoma, Papillary - enzymology | Hypertension - epidemiology | Adenoma, Oxyphilic - radiotherapy | Drug Eruptions - etiology | Phenylurea Compounds - therapeutic use | Dyspnea - epidemiology | Disease-Free Survival | Carcinoma, Papillary - radiotherapy | Fatigue - epidemiology | Thyroid Neoplasms - drug therapy | Protein Kinase Inhibitors - therapeutic use | Aged | Diarrhea - drug therapy | Drug Eruptions - epidemiology | Radiopharmaceuticals - therapeutic use | Index Medicus | Research
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2012, Volume 30, Issue 21, pp. 2654 - 2663
Purpose The frequency of BRCA1 and BRCA2 germ-line mutations in women with ovarian cancer is unclear; reports vary from 3% to 27%. The impact of germ-line... 
POLY(ADP-RIBOSE) POLYMERASE | CLEAR-CELL | ONCOLOGY | RESISTANCE | IMPROVED SURVIVAL | HOMOLOGOUS RECOMBINATION | CARCINOMA | CARRIERS | TUMORS | CHEMOTHERAPY | FEATURES | Medical History Taking | Recurrence | Prospective Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Drug Resistance, Neoplasm | Cystadenocarcinoma, Serous - genetics | Cystadenocarcinoma, Serous - drug therapy | Case-Control Studies | Ovarian Neoplasms - genetics | Peritoneal Neoplasms - drug therapy | Neoplasm Grading | Fallopian Tube Neoplasms - genetics | Aged, 80 and over | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Genes, BRCA1 | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Carcinoma - drug therapy | Carcinoma, Endometrioid - genetics | Kaplan-Meier Estimate | Mutation Rate | Treatment Outcome | Carcinoma, Endometrioid - drug therapy | Australia - epidemiology | Ovarian Neoplasms - epidemiology | Disease-Free Survival | Point Mutation | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Peritoneal Neoplasms - genetics | Carcinoma - genetics | Aged | Platinum Compounds - administration & dosage | Neoplasm Staging | Adenocarcinoma, Clear Cell - genetics | Adenocarcinoma, Clear Cell - drug therapy | Cohort Studies | Original Reports | Gynecologic Cancer | Gync21 | Gync15
Journal Article